Northumbria University, Newcastle-Upon-Tyne, UK.
Imperial College London, London, UK.
Clin Nurs Res. 2022 Jul;31(6):1107-1123. doi: 10.1177/10547738221092146. Epub 2022 Apr 28.
Sleep disturbance is one of the most common and troubling symptoms that harm the quality of life throughout all phases of treatment and stages of the illness among patients with cancer. The aim of this meta-analysis is to examine the present status of sleep disturbance prevalence in patients with cancer. The following databases were searched: PubMed, CINAHL, MEDLINE, EMBASE, PsycINFO, from inception to April 2021. Prevalence rates were pooled with meta-analysis using a random-effects model. A total of 160 studies ( = 46,279) published between 1998 and 2021 met the inclusion criteria. The overall prevalence of sleep disturbance was 60.7% (26,448/46,279 participants, 95% CI 58.1-63.3%) with significant heterogeneity between studies ( < .000, = .0000, = 96.4%). This meta-analysis highlights the importance of developing optimal monitoring strategies to reduce sleep disturbance and improve the quality of life of cancer patients.
睡眠障碍是癌症患者在治疗的各个阶段和疾病的各个阶段中最常见和最困扰的症状之一，它会损害生活质量。本荟萃分析旨在研究癌症患者睡眠障碍的现状。检索了以下数据库：PubMed、CINAHL、MEDLINE、EMBASE、PsycINFO，从建立到 2021 年 4 月。使用随机效应模型对患病率进行荟萃分析。共有 160 项研究（ = 46279）发表于 1998 年至 2021 年，符合纳入标准。睡眠障碍的总体患病率为 60.7%（26448/46279 名参与者，95%CI 58.1-63.3%），研究之间存在显著异质性（ < .000， = .0000， = 96.4%）。本荟萃分析强调了制定最佳监测策略以减少睡眠障碍和提高癌症患者生活质量的重要性。
